3.72
-0.02 (-0.40%)
| Previous Close | 3.73 |
| Open | 3.73 |
| Volume | 327,659 |
| Avg. Volume (3M) | 686,889 |
| Market Cap | 240,350,832 |
| Price / Book | 1.27 |
| 52 Weeks Range | |
| Earnings Date | 11 Nov 2026 |
| Diluted EPS (TTM) | -1.97 |
| Total Debt/Equity (MRQ) | 9.76% |
| Current Ratio (MRQ) | 7.48 |
| Operating Cash Flow (TTM) | -53.59 M |
| Levered Free Cash Flow (TTM) | -32.40 M |
| Return on Assets (TTM) | -57.90% |
| Return on Equity (TTM) | -102.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Immuneering Corporation | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | 0.50 |
Select this tab to load the latest available analysis.
|
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 24.12% |
| % Held by Institutions | 12.55% |
No data within this time range.
No data within this time range.
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |